Low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolemia: Two lifetime journeys of lipid-lowering therapy

J Clin Lipidol. 2017 Jan-Feb;11(1):301-305. doi: 10.1016/j.jacl.2017.01.004. Epub 2017 Jan 12.

Abstract

We present the case history of 2 patients with low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolemia who did not receive lipoprotein apheresis. We describe the subsequent effect of all lipid-lowering medications during their life course including resins, statins, ezetimibe, nicotinic acid/laropiprant, mipomersen, and lomitapide. These cases tell the story of siblings affected with this rare disease, who are free of symptoms but still are at a very high cardiovascular disease risk, and their treatment from childhood.

Keywords: Homozygous familial hypercholesterolemia; Lipid lowering; Lomitapide; Mipomersen; Treatment.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Heterozygote*
  • Humans
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type II / genetics*
  • Hyperlipoproteinemia Type II / metabolism
  • Hypolipidemic Agents / pharmacology*
  • Hypolipidemic Agents / therapeutic use
  • Male
  • Receptors, LDL / metabolism
  • Young Adult

Substances

  • Hypolipidemic Agents
  • Receptors, LDL